U.S. markets closed

Cryo-Cell International, Inc. (CCEL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
11.86-0.14 (-1.20%)
At close: 3:30PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close12.00
Open12.23
Bid11.67 x 1000
Ask12.25 x 1800
Day's Range11.86 - 12.23
52 Week Range6.45 - 14.16
Volume798
Avg. Volume6,030
Market Cap100.123M
Beta (5Y Monthly)0.35
PE Ratio (TTM)24.70
EPS (TTM)0.48
Earnings DateApr 14, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-12% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cryo-Cell International, Inc.
    PKI: Lowering target price to $195.00PERKINELMER INC has an Investment Rating of HOLD; a target price of $195.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    Cryo-Cell International Announces Uplisting to The Nasdaq Capital Market

    Cryo-Cell International, Inc. (Symbol CCEL), The Leader In Cord Blood And Cord Tissue Cryopreservation Services, Today Announced That The Company’s Common Stock Has Been Approved For Listing On The Nasdaq Capital Market (“Nasdaq”). Trading to Begin August 31, 2021 with Current Ticker “CCEL” MIAMI, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International has met Nasdaq’s stringent financial, liquidity and corporate governance listing requirements. As a result, Cryo-Cell will be listed on Nasdaq

  • GlobeNewswire

    Cryo-Cell International Completes Acquisition of Real Estate Property for Its Institute for Cellular Therapies

    Cryo-Cell International (symbol: CCEL) Purchases Real Estate Location for its Institute for Cellular Therapies in the Raleigh-Durham area. MIAMI, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell Institute for Cellular Therapies’ first clinic site is‎ conveniently located in Durham NC, near the Raleigh-Durham International Airport (International Airport). The ‎8,326 sq. ft. facility is well situated, with several nearby hotels to choose from for the families that are expected to be traveling from all

  • Newsfile

    Cryo-Cell International to Present at the Q3 Virtual Investor Summit on August 18, 2021

    Oldsmar, Florida--(Newsfile Corp. - August 11, 2021) - Cryo-Cell International (OTC Pink: CCEL) today announced that David Portnoy, Chairman of the board and Co-CEO will be attending the Q3 Virtual Investor Summit. Event Q3 Investor Summit Date August 17-18th, 2021 Presentation August 18th at 02:45 PM ET Location https://zoom.us/webinar/register/WN_mUXIsyaBSl6hpoY8M7ZNpA About Cryo-Cell InternationalFounded in 1989, Cryo-Cell International Inc., the world’s first private cord blood bank, is inte